Progress of circulating tumor cells in clinical application

doi:10.3760/cma.j.issn.1673-422X.2018.09.009

Abstract

Abstract: Circulating tumor cells (CTCs) are cancerous cells that shed from the primary tumor or metastases into the bloodstream. The currently clinical applicability of CTCs approved by the US Food and Drug Administration (FDA) is that CTCs can be prognostic biomarker for patients with metastatic breast cancer, prostate cancer and colorectal cancer. CTCs also have great potential in the prognosis assessment of other metastatic or localized tumors, as well as early screening of tumors, analysis of molecular profiling, guiding treatment decisions, and monitoring of treatment response. Currently, various studies are being carried out to further explore the clinical application of CTCs, and provide new strategies and new prospects for individualized and precise treatment of cancer patients.

Key words: Neoplasm circulating cells, Diagnosis, Prognosis, Liquid biopsy

Chen Luojun, Li Na, Tian Jingyuan, Song Qibin, Yu Jinming. Progress of circulating tumor cells in clinical application[J]. Journal of International Oncology, 2018, 45(8): 552-555.

References

［1］ Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: clinical validity and utility［J］. Int J Clin Oncol, 2017, 22(3): 421430. DOI: 10.1007/s1014701711052. ［2］ Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data［J］. Lancet Oncol, 2014, 15(4): 406414. DOI: 10.1016/S14702045(14)700695. ［3］ Huang X, Gao P, Song Y, et al. Metaanalysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer［J］. BMC Cancer, 2015, 15: 202. DOI: 10.1186/s1288501512189. ［4］ Unger JM, Griffin K, Donaldson GW, et al. Patientreported outcomes for patients with metastatic castrationresistant prostate cancer receiving docetaxel and atrasentan versus docetaxel and placebo in a randomized phase Ⅲ clinical trial (SWOG S0421)［J］. J Patient Rep Outcomes, 2017, 2: 27. DOI: 10.1186/s4168701800545. ［5］ Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmallcell lung cancer［J］. J Clin Oncol, 2011, 29(12): 15561563. DOI: 10.1200/JCO.2010.28.7045. ［6］ Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a metaanalysis［J］. J Natl Cancer Inst, 2018, 110(6): 560567. DOI: 10.1093/jnci/djy018. ［7］ Bork U, Rahbari NN, Scholch S, et al. Circulating tumour cells and outcome in nonmetastatic colorectal cancer: a prospective study［J］. Br J Cancer, 2015, 112(8): 13061313. DOI: 10.1038/bjc.2015.88. ［8］ Syrigos K, Fiste O, Charpidou A, et al. Circulating tumor cells count as a predictor of survival in lung cancer［J］. Crit Rev Oncol Hematol, 2018, 125: 6068. DOI: 10.1016/j.critrevonc.2018.03.004. ［9］ Davis JW, Nakanishi H, Kumar VS, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer［J］. J Urol, 2008, 179(6): 21872191. DOI: 10.1016/j.juro.2008.01.102. ［10］ Fiorelli A, Accardo M, Carelli E, et al. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis［J］. Ann Thorac Surg, 2015, 99(6): 18991905. DOI: 10.1016/j.athoracsur.2014.11.049. ［11］ Ilie M, Hofman V, LongMira E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease［J］. PLoS One, 2014, 9(10): e111597. DOI: 10.1371/journal.pone.0111597. ［12］ Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lungcancer cells［J］. N Engl J Med, 2008, 359(4): 366377. DOI: 10.1056/NEJMoa0800668. ［13］ Sundaresan TK, Sequist LV, Heymach JV, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive bloodbased analyses［J］. Clin Cancer Res, 2016, 22(5): 11031110. DOI: 10.1158/10780432.Ccr151031. ［14］ Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue［J］. Int J Cancer, 2013, 133(1): 130141. DOI: 10.1002/ijc.27987. ［15］ Mohamed Suhaimi NA, Foong YM, Lee DY, et al. Noninvasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients［J］. Mol Oncol, 2015, 9(4): 850860. DOI: 10.1016/j.molonc.2014.12.011. ［16］ Wang CH, Chang CJ, Yeh KY, et al. The prognostic value of HER2positive circulating tumor cells in breast cancer patients: a systematic review and metaanalysis［J］. Clin Breast Cancer, 2017, 17(5): 341349. DOI: 10.1016/j.clbc.2017.02.002. ［17］ Fehm T, Muller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial［J］. Breast Cancer Res Treat, 2010, 124(2): 403412. DOI: 10.1007/s105490101163x. ［18］ Miyamoto DT, Zheng Y, Wittner BS, et al. RNASeq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance［J］. Science, 2015, 349(6254): 13511356. DOI: 10.1126/science.aab0917. ［19］ Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant7 mRNA detection in circulating tumor cells of men with metastatic castrationresistant prostate cancer treated with first and secondline abiraterone and enzalutamide［J］. J Clin Oncol, 2017, 35(19): 21492156. DOI: 10.1200/JCO.2016.70.1961. ［20］ Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapyresistant CK19mRNApositive circulating tumor cells: results of a randomized phase Ⅱ study［J］. Ann Oncol, 2012, 23(7): 17441750. DOI: 10.1093/annonc/mds020. ［21］ Hainsworth JD, Murphy PB, Alemar JR, et al. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2negative metastatic breast cancer: lack of response to HER2targeted therapy［J］. Breast Cancer Res Treat, 2016, 160(1): 4149. DOI: 10.1007/s1054901639697. ［22］ Krebs MG, Renehan AG, Backen A, et al. Circulating tumor cell enumeration in a phase Ⅱ trial of a fourdrug regimen in advanced colorectal cancer［J］. Clin Colorectal Cancer, 2015, 14(2): 115122. DOI: 10.1016/j.clcc.2014.12.006. ［23］ Goodman OB Jr, Symanowski JT, Loudyi A, et al. Circulating tumor cells as a predictive biomarker in patients with hormonesensitive prostate cancer［J］. Clin Genitourin Cancer, 2011, 9(1): 3138. DOI: 10.1016/j.clgc.2011.04.001. ［24］ Pearl ML, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)［J］. Gynecol Oncol, 2015, 137(2): 229238. DOI: 10.1016/j.ygyno.2015.03.002. ［25］ Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500［J］. J Clin Oncol, 2014, 32(31): 34833489. DOI: 10.1200/jco.2014.56.2561.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[8]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[9]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[10]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[11]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[14]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[15]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.